NPC-REAAD EBV Early Antigen Antibody ELISA
The NPC-REAAD EBV Early Antigen Antibody ELISA is For Research Use Only
Size: 1×96 wells
Sensitivity: 103 RU
Standard Range: 103 – 127 RU
Incubation Time: 1.25 hours
Sample Type: Serum
Sample Size: 100 µl
Alternative Names: Nasopharyngeal Cancer, Epstein Barr Virus, EBV EA IgA
Controls Included
Assay Background
Nasopharyngeal Cancer (NPC) is closely associated with the infection of Epstein Barr Virus (EBV), a virus belonging to the Herpes Virus family. The virus has also been implicated in diseases such as Infectious Mononucleosis (IM), Burkitt’s lymphoma and Hodgkin’s disease. NPC-REAAD™ uses 4 highly NPC-specific polypeptides generated by DNA recombinant technology to detect the presence of EBV proteins known to be associated with NPC. These polypeptides are known as EA-D, RR-L RR-S and the other is a novel proprietary protein discovered by Restalyst during development of NPC-REAAD™. Studies have shown that their combined specificity to NPC patients’ serum increased significantly, enabling discrimination of NPC from non-NPC samples. The Test uses an arbitrary unit of measurement known as REAAD™-units (RU). A variety of commercial assays are available to detect acute or chronic EBV infections based on anti-EBV IgG, IgM or IgA antibodies against antigens such as VCA, EA and EBNA-1.
Related Products
HCC-REAAD ErbB3 ELISA Assay
GC-REAAD™ ITIH3 ELISA Assay
DM1 Antibody Drug Conjugate (ADC) ELISA Assay Kit
Product manufactured by Restalyst.
